Gilde raises additional capital for healthcare service investments - Gilde Healthcare

Gilde raises additional capital for healthcare service investments

12. Oktober 2011

Utrecht – Gilde Healthcare Partners has raised more than €50 million for its Gilde Healthcare Services fund. The fund invests growth capital in specialist clinics, elderly care, primary care, disease prevention, mental health, service laboratories and other healthcare service sectors.

“Innovative, expanding healthcare companies are in need of capital investment to support growth and this type of finance is often difficult to source from banks and governments in the current economic climate”

says Managing Partner Pieter van der Meer.

“As a value added partner providing growth capital Gilde can support the growth of various healthcare services companies.”, according to Jasper van Gorp, partner of the fund, “We are particularly focused on companies that provide quality care in a cost effective way.”

In 2010, the Gilde Healthcare Services fund invested in Stepping Stones Home & Care, a chain of small scale nursing homes for the elderly. The fund expects to announce an additional new investment in the coming weeks.

The fund complements existing Gilde Healthcare funds, which invest in companies developing medicines, diagnostic products and medical devices.

Mehr neuigkeiten

Hermann Medizintechnik wird Teil von SPI, der spezialisierten MedTech CDMO-Plattform von Gilde Healthcare

Hermann Medizintechnik („Hermann") hat sich offiziell der Gruppe von Auftragsfertigern für komplexe chirurgische Instrumente und Implantate von Gilde Healthcare („SPI") angeschlossen. Damit erreicht SPI einen weiteren bedeutenden Meilenstein. Mit Hermann wächst SPI auf mehr als...
10. September 2026

BENTEC Endoscopy schließt sich der Auftragsfertigungsgruppe von Gilde Healthcare für chirurgische Instrumente und Implantate an

Die Gruppe von Auftragsfertigern für komplexe chirurgische Instrumente und Implantate von Gilde Healthcare („SPI") übernimmt BENTEC Endoscopy („BENTEC"). Die Transaktion ist ein weiterer bedeutender Meilenstein beim Aufbau einer führenden Gruppe für die Auftragsfertigung chirurgischer Instrumente....
27. August 2026

Gilde Healthcare portfolio company Synox Therapeutics announces positive topline results from the Phase 3 TANGENT study

TANGENT met its primary and secondary endpoints with a high level of statistical significance vs. placebo at 6 months, including ORR by RECIST V1.1 and Tumor Volume Score (TVS), and clinically meaningful improvements in PROMIS-PF...
13. April 2026